

July 6 & 7, 2017

Institut Pasteur

3rd Paris NASH Symposium

French-US Think Tank

Organized by
Prof. Arun Sanyal
& Prof. Lawrence Serfaty

With the partnership of



08:30 - 08:35 am

Welcome Remarks by Lawrence Serfaty (FR)

08:35 - 08:45 am

Inauguration Address by Stanislas Pol (FR)**08:45 - 10:15 am****Session 1 • NASH in other settings**

Chairs: Arun Sanyal (US) and Patrick Marcellin (FR)

08:45 - 09:00 am

NASH in HIV: how big is the problem? - Maud Lemoine (UK)

09:00 - 09:15 am

Are the therapeutic targets for NASH in HIV the same as in garden-variety NASH? - Richard Sterling (US)

09:15 - 09:30 am

The burden of NASH before and after liver transplantation - Rajender Reddy (US)

09:30 - 09:45 am

Is NASH responsible for disease progression after SVR in subjects with HCV? - Lawrence Serfaty (FR)

09:45 - 10:15 am

Discussion

10:15 - 10:45 am

*COFFEE BREAK AND POSTERS (EXHIBITION AREA)***10:45 - 11:50 am****Session 2 • GETTING TO THE HEART OF THE MATTER**

Chairs: Bruno Vergès (FR) and Ariel Cohen (FR)

10:45 - 11:00 am

Atherogenic risk factors and cardiac outcomes in NASH - Raluca Pais (FR)

11:00 - 11:15 am

NASH and the myocardium - Mohammad Siddiqui (US)

11:15 - 11:30 am

QTc and NASH-from molecular biology to clinical significance - Franck Boccara (FR)

11:30 - 11:50 am

Discussion**11:50 - 12:55 pm****Session 3 • CLINICAL HOT TOPICS**

Chairs: Mohammad Siddiqui (US) and Philippe Mathurin (FR)

11:50 - 12:05 pm

Disease burden report for Europe - Homie Razavi (US)

12:05 - 12:20 pm

Prospective assessment of disease evolution in NASH - Arun Sanyal (US)

12:20 - 12:35 pm

DILI phenotypes and its assessment in NASH - Robert Fontana (US)

12:35 - 12:55 pm

Discussion

01:00 - 02:00 pm	<i>LUNCH AND POSTERS</i>
02:00 - 03:30 pm	Session 4 • THE ROLE OF THE GUT IN NASH Chairs: Lawrence Serfaty (FR) and Gyongyi Szabo (US)
02:00 - 02:15 pm	Plasticity of the mucosal barrier: Insights into regulation of the Intestinal Epithelial Barrier and Steatohepatitis Asma Nusrat (US)
02:15 - 02:30 pm	Endocrine signaling from the gut and its implications for NASH - Bart Staels (FR)
02:30 - 02:45 pm	Impact of macronutrient constituents of diet on NASH phenotype and outcomes - Jean-Francois Dufour (CH)
02:45 - 03:00 pm	Diet-microbiome interactions and NASH - Puneet Puri (US)
03:00 - 03:30 pm	Discussion
03:30 - 04:00 pm	<i>COFFEE BREAK AND POSTERS (EXHIBITION AREA)</i>
04:00 - 05:30 pm	Session 5 • INFLAMMATION Chairs: Alexandre Louvet (FR) and Stanislas Pol (FR)
04:00 - 04:15 pm	Gut derived activators of inflammation in NASH - Gyongyi Szabo (US)
04:15 - 04:30 pm	Intrahepatic intracellular activators of innate immunity in NASH - Wajahat Mehal (US)
04:30 - 04:45 pm	Role of macrophages in disease development and progression - Frank Tacke (DE)
04:45 - 05:00 pm	Adipose tissue inflammation in type 2 diabetes and NASH - Karine Clement (FR)
05:00 - 05:30 pm	Discussion
05:30 - 06:35 pm	Session 6 • TECHNOLOGIC INNOVATIONS IN NASH Chairs: Rohit Loomba (US) and Jean-Pierre Bronowicki (FR)
05:30 - 05:45 pm	Hijacking the microbiome to modify NASH - Dean Falb (US)
05:45 - 06:00 pm	Endoscopic treatment of Diabetes and NASH - Harith Rajagopalan (US)
06:00 - 06:15 pm	Nanoparticle based anti-fibrotic therapies in NASH - Wenbin Ying (US)
06:15 - 06:35 pm	Discussion
06:35 - 06:45 pm	The Copper - NAFLD connection: Role of hepatic copper deficiency - Peter Ferenci (AT)
06:45 - 07:15 pm	POSTER AWARDS & RECEPTION / NEW THIS YEAR

08:30 - 09:00 am

CONFERENCE OPENING

09:00 - 10:30 am

Session 7 • INNOVATIONS IN FIBROSIS ASSESSMENT

Chairs: Pierre Bedossa (FR) and Scott Friedman (US)

09:00 - 09:15 am

New algorithms for assessment of fibrosis in NAFLD - Jérôme Boursier (FR)

09:15 - 09:30 am

Dual photon microscopy and its potential for assessing fibrosis evolution - Arun Sanyal (US)

09:30 - 09:45 am

Potential role of deuterated markers in assessment of fibrosis - Rohit Loomba (US)

09:45 - 10:00 am

Assessing fibrosis using antibodies to collagen epitopes - Morten Karsdal (DK)

10:00 - 10:30 am

Discussion

10:30 - 11:00 am

COFFEE BREAK (EXHIBITION AREA)

11:00 - 12:05 pm

Session 8 • SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT

Chairs: Mark DeLegge (US) and Dominique Larrey (FR)

11:00 - 11:15 am

Seamless drug development paradigms - Claudia Filozof (UK)

11:15 - 11:30 am

Point of Care tests for the diagnosis of NASH in clinical trials, design consideration and potential use - Karine Lacombe (FR)

11:30 - 11:45 am

Causality assessment in large data: potential applications for NASH - Antoine Chambaz (FR)

11:45 - 12:05 pm

Discussion

12:05 - 12:30 pm

Session 9 • REGULATORY LANDSCAPE

Chair: Lawrence Serfaty (FR)

12:05 - 12:20 pm

What is new on the regulatory front? - Veronica Miller (US)

12:20 - 12:30 pm

Discussion

12:30 - 01:45 pm

WORKING LUNCHESES SESSION / NEW THIS YEAR

Group 1:

Transatlantic Biomarker Development

Julia Brosnan (US) and Sudha Shankar (US)

Group 2:

NASH cohorts for clinical trials around the world

Arun Sanyal (US) and Vlad Ratziu (FR)

Group 3:

The place of bariatric surgery in NASH: can we extend the indications?

Philippe Mathurin (FR) and Nicolas Goossens (CH)

01:45 - 02:15 pm

SESSION 10 • State of the art lecture

Chair: Arun Sanyal (US)

Past, present and future of therapeutics for liver fibrosis

Scott Friedman (US)

02:15 - 03:45 pm

SESSION 11 • INDUSTRY FORUM

Chairs: Lawrence Serfaty (FR) and Arun Sanyal (US)

02:15 - 03:15 pm

SPONSOR SESSION

03:15 - 03:45 pm

Panel Discussion

03:45 pm

Closing Remarks by Arun Sanyal (US)

NEW THIS YEAR!

Posters session in the Exhibition Area

Thursday, July 6 at 10:15 am, 01:00 pm and 3:30 pm

Poster Award & Reception at 06:45 pm

Working Lunches Session

Friday, July 7 from 12:30 to 01:45 pm

3 working lunches

(no regular lunch on friday)





*PDF presentations of the
3rd Paris Nash Symposium
will be available on the websites:*

www.paris-nash-symposium.org

www.hivforum.org



July 6 & 7, 2017
Institut Pasteur

3rd Paris NASH Symposium

French-US Think Tank

Supported by

